Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Danirixin HBr vs Free Base in Healthy Elderly
NCT02453022Phase 1Completed
- Sponsor
- GSK
- Start
- May 2015
- Primary completion
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of danirixin in chronic obstructive pulmonary disease (COPD), sponsored by GSK. Primary endpoints: Composite of Danirixin PK parameters at 48 hours, Number of participants with adverse events (AE) /serious adverse event (SAE) and 3 more. Started May 2015; status: completed.
02
Drugs
danirixin
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02453022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02453022.